Unter den Linden 10
Berlin 10117
Germany
49 30 700 140 449
https://www.aladdinid.com
Sector(s): Healthcare
Industry: Health Information Services
Full-time employees: 3
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Wade Menpes-Smith | Chairman of the Board, CEO & MD | N/A | N/A | N/A |
Mr. Bimal Shah | Deputy Chairman & COO | N/A | N/A | N/A |
Mr. Hamish Badenoch | CFO & Director | N/A | N/A | N/A |
Prof. David C. Rubinsztein | Member of Drug Discovery Advisory Board & Chief Scientific Advisor | N/A | N/A | N/A |
Mr. Paul Sitoh | Head of Blockchain Technology | N/A | N/A | N/A |
Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. The company provides Artificial Intelligence assisted Drug Discovery platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2; PharmaKG, a biomedical knowledge graph; and Disease Diagnosis and Risk Assessment Platform. The company was founded in 2014 and is based in Berlin, Germany.
Aladdin Blockchain Technologies Holding SE ’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.